Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 671013, 8 pages
http://dx.doi.org/10.1155/2014/671013
Research Article

Effects of Chaihu-Shugan-San and Shen-Ling-Bai-Zhu-San on p38 MAPK Pathway in Kupffer Cells of Nonalcoholic Steatohepatitis

1Medical School of Jinan University, 601 Huangpu Road West, Guangzhou, Guangdong 510632, China
2Experimental Animal Management Center of Jinan University, 601 Huangpu Road West, Guangzhou, Guangdong 510632, China

Received 28 October 2013; Accepted 22 February 2014; Published 25 March 2014

Academic Editor: Kashmira Nanji

Copyright © 2014 Qin-He Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Chen, J. S. Zhu, and J. P. Ren, “Protective and curative effects of Chaihu Shugan San (CHSGS) on acute liver injury caused by carbon tetrachloride in rats,” Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, vol. 14, no. 1, pp. 42–43, 2004. View at Google Scholar
  2. S.-Q. Li, Z.-H. Su, J.-B. Peng, Z.-M. Zou, and C.-Y. Yu, “In vitro and in vivo antioxidant effects and the possible relationship between the antidepression efficacy of traditional Chinese medicine formulation Chaihu Shugan San,” Chinese Journal of Natural Medicines, vol. 8, no. 5, pp. 353–361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. D. C. Fu, S. Z. Yang, X. F. Song, and Y. Xiao, “Effect of Chaihu Shugan San in treating liver fibrosis,” Chinese Journal of Gerontology, vol. 27, no. 6, pp. 1146–1148, 2007. View at Google Scholar
  4. F. M. Pang, D. X. Zhang, and J. R. Huang, “Effect of Chaihu Shugan San on B ultrasonic and the index of liver fibrosis in nonalcoholic fatty liver disease patient,” Journal of Sichuan of Traditional Chinese Medicine, vol. 27, no. 2, pp. 66–67, 2009. View at Google Scholar
  5. C. R. Xue and X. L. Zhou, “Glycometabolism in chronic pancreatitis and intervening effect of Chaihu Shugan San,” Chinese Journal of Surgery of Integrated Traditional and Western Medicine, vol. 16, no. 2, pp. 189–191, 2010. View at Google Scholar
  6. Y. You, Y. H. Liu, and S. L. Gao, “Effect and mechanism of Shenling Baizhu San on the murine model of inflammatory bowel disease induced by dextran sodium sulfate in mice,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 18, no. 5, pp. 136–140, 2012. View at Google Scholar
  7. Z.-H. Li, J. Wang, Y.-W. Wang, R.-L. Cai, J. Sun, and M.-G. Ye, “Effect of shenlingbaizhu powder on serum levels of EGF, SOD and MDA in ulcerative colitis rats with syndrome of dampness stagnancy due to spleen deficiency,” World Chinese Journal of Digestology, vol. 20, no. 5, pp. 410–413, 2012. View at Google Scholar · View at Scopus
  8. X. P. Liu, Y. X. Jia, Q. Liu, and J. J. Wu, “Effects of Shenglingbaizhusan decoction on CD44, D62p and CD54 in ulcerative colitis rats with asthenia of spleen,” Lishizhen Medicine and Materia Medica Research, vol. 22, no. 11, pp. 2671–2673, 2011. View at Google Scholar
  9. H. Y. Ge, B. Chen, H. L. Liu, and H. Q. Li, “Protective effect of Bupleurum Saikosaponin on alcoholic liver disease in rats,” Chinese Journal of Gerontology, vol. 31, no. 4, pp. 662–663, 2011. View at Google Scholar
  10. L.-C. Chiang, L. T. Ng, L.-T. Liu, D.-E. Shieh, and C.-C. Lin, “Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from Bupleurum species,” Planta Medica, vol. 69, no. 8, pp. 705–709, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. C. W. Zheng, H. M. Ding, Y. Chen, and Y. B. Feng, “Experimental study of saikosaponin on hepatic fibrosis in rats,” Journal of Emergency in Traditional Chinese Medicine, vol. 20, no. 5, p. 755, 2011. View at Google Scholar
  12. Y. L. Liu and J. H. Lv, “Hypolipidemic and antioxidative effect and hepatic protective effect of total glucosides of peony's on non-alcoholic fatty liver,” Journal of Hainan Medical College, vol. 18, no. 2, pp. 158–161, 2012. View at Google Scholar
  13. R. X. Zhao, L. Y. Zheng, J. Q. Pan et al., “The antioxidative mechanism of total glucosides of paeony on protection against the fatty liver in NAFLD rats,” Journal of Guangdong College of Pharmacy, vol. 28, no. 4, pp. 430–434, 2012. View at Google Scholar
  14. J. Zeng, F. Li, X. M. Jia, and C. Y. Li, “Comparison of the effects of Ginsenoside Rg3 and IFN-alpha on hepatic fibrosis induced by schistosomiasis japonica in mice,” Journal of Pathogen Biology, vol. 6, no. 11, pp. 825–827, 2011. View at Google Scholar
  15. Y.-G. Li, D.-F. Ji, S. Zhong, X.-L. Zheng, and L.-G. Shi, “Protective effect of saponins extracted from Panax japonicus on ethanol-induced hepatic cells L-O2 injury,” Chinese Journal of Pharmacology and Toxicology, vol. 25, no. 3, pp. 289–295, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. C. H. Wang, Q. G. Geng, and Y. X. Wang, “Protective effect of atractylenolide I on immunological liver injury,” China Journal of Chinese Materia Medica, vol. 37, no. 12, pp. 1809–1812, 2012. View at Google Scholar
  17. J. Zhang, X. N. Liu, P. J. Zhang et al., “Effect of atractylodes macrocephalaon polysaccharide pre-disposal treatment after ischemia reperfusion injury of liver on the chondriosome structure of hepatic cell in rats,” Journal of Hepatopancreatobiliary Surgery, vol. 23, no. 1, pp. 4–6, 2011. View at Google Scholar
  18. W. Zhou, Y. Hu, H. W. Zhang et al., “Effect of carboxymethylpachymaran on signal-transduction of TGF beta-Smad on hepatic fibrosis in rats,” Chinese Journal of Ethnomedicine and Ethnopharmacy, vol. 18, no. 20, pp. 16–18, 2009. View at Google Scholar
  19. P. Angulo, “Medical progress: monalcoholic fatty liver disease,” New England Journal of Medicine, vol. 346, no. 16, pp. 1221–1231, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Vanni, E. Bugianesi, A. Kotronen, S. De Minicis, H. Yki-Järvinen, and G. Svegliati-Baroni, “From the metabolic syndrome to NAFLD or vice versa?” Digestive and Liver Disease, vol. 42, no. 5, pp. 320–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. K. L. Kopec and D. Burns, “Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy,” Nutrition in Clinical Practice, vol. 26, no. 5, pp. 565–576, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Kimura, S. Sekiguchi, S. Hayashi et al., “Role of interleukin-18 in intrahepatic inflammatory cell recruitment in acute liver injury,” Journal of Leukocyte Biology, vol. 89, no. 3, pp. 433–442, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Valatas, G. Kolios, P. Manousou et al., “Secretion of inflammatory mediators by isolated rat Kupffer cells: the effect of octreotide,” Regulatory Peptides, vol. 120, no. 1–3, pp. 215–225, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. H. F. Escobar-Morreale, R. M. Calvo, J. Sancho, and J. L. San Millán, “TNF-α and hyperandrogenism: a clinical, biochemical, and molecular genetic study,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3761–3767, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Spielmann, T. Kerner, O. Ahlers, D. Keh, M. Gerlach, and H. Gerlach, “Early detection of increased tumour necrosis factor alpha TNFα) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course,” Acta Anaesthesiologica Scandinavica, vol. 45, no. 3, pp. 364–370, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Baffy, “Kupffer cells in non-alcoholic fatty liver disease: the emerging view,” Journal of Hepatology, vol. 51, no. 1, pp. 212–223, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. Q. H. Yang, S. P. Hu, Y. P. Zhang et al., “Effects of different therapeutic methods and typical recipes of traditional Chinese medicine on activation of c-Jun N-terminal kinase in Kupffer cells of rats with fatty liver disease,” Chinese Journal of Integrative Medicine, vol. 18, no. 10, pp. 769–774, 2012. View at Publisher · View at Google Scholar
  28. Q. H. Yang, F. Xie, F. Z. Wang et al., “Effect of different therapies on hepatic nuclear factor κBp65 and Kupffer cell p38 MAPK expression in rats with fatty liver,” Journal of Guangzhou University of Traditional Chinese Medicine, vol. 27, no. 2, pp. 141–147, 2009. View at Google Scholar
  29. Q.-H. Yang, S.-P. Hu, Y.-P. Zhang et al., “Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats,” Chinese Journal of Integrative Medicine, vol. 17, no. 3, pp. 205–211, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. X. Y. Shi, Experimental Zoology of Modern Medicine, People's Military Medical Press, Beijing, China, 1st edition, 2000.
  31. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. G. F. Feng, Q. H. Yang, W. J. Wang et al., “Simultaneously isolation and identification of hepatocytes and Kupffer cells from nonalcoholic steatohepatitis rat,” Guangdong Medical Journal, vol. 33, no. 1, pp. 40–43, 2012. View at Google Scholar
  33. J. C. Cohen, J. D. Horton, and H. H. Hobbs, “Human fatty liver disease: old questions and new insights,” Science, vol. 332, no. 6037, pp. 1519–1523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Fuchs, “Non-alcoholic fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment target,” Journal of Lipids, vol. 2012, Article ID 934396, 8 pages, 2012. View at Publisher · View at Google Scholar
  35. Y. Yimin, H. Furumaki, S. Matsuoka et al., “A novel murine model for non-alcoholic steatohepatitis developed by combination of a high-fat diet and oxidized low-density lipoprotein,” Laboratory Investigation, vol. 92, no. 2, pp. 265–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Tilg and A. M. Diehl, “Mechanisms of disease: cytokines in alcoholic and nonalcoholic steatohepatitis,” New England Journal of Medicine, vol. 343, no. 20, pp. 1467–1467, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Kudo, T. Takahara, Y. Yata, K. Kawai, W. Zhang, and T. Sugiyama, “Lipopolysaccharide triggered TNF-α-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model,” Journal of Hepatology, vol. 51, no. 1, pp. 168–175, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Choi and A. M. Diehl, “Role of inflammation in nonalcoholic steatohepatitis,” Current Opinion in Gastroenterology, vol. 21, no. 6, pp. 702–707, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Kamari, A. Shaish, E. Vax et al., “Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice,” Journal of Hepatology, vol. 55, no. 5, pp. 1086–1094, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. P. F. Lalor, J. Faint, Y. Aarbodem, S. G. Hubscher, and D. H. Adams, “The role of cytokines and chemokines in the development of steatohepatitis,” Seminars in Liver Disease, vol. 27, no. 2, pp. 173–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Tilg and A. R. Moschen, “Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis,” Hepatology, vol. 52, no. 5, pp. 1836–1846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Ji, Q. Yang, J. Hao et al., “Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms,” International Immunopharmacology, vol. 11, no. 6, pp. 762–768, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. P. P. Roux and J. Blenis, “ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions,” Microbiology and Molecular Biology Reviews, vol. 68, no. 2, pp. 320–344, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. E. F. Wagner and Á. R. Nebreda, “Signal integration by JNK and p38 MAPK pathways in cancer development,” Nature Reviews Cancer, vol. 9, no. 8, pp. 537–549, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. S. Jin and J.-O. Lee, “Structures of the toll-like receptor family and its ligand complexes,” Immunity, vol. 29, no. 2, pp. 182–191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Takeda and S. Akira, “TLR signaling pathways,” Seminars in Immunology, vol. 16, no. 1, pp. 3–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Liu, Z. Zhang, L. Wang et al., “TLR4 monoclonal antibody blockade suppresses dextran-sulfate-sodium-induced colitis in mice,” Journal of Gastroenterology and Hepatology, vol. 25, no. 1, pp. 209–214, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Alisi, N. Panera, and V. Nobili, “Toll-like receptor 4: a starting point for proinflammatory signals in fatty liver disease,” Hepatology, vol. 51, no. 2, pp. 714–715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Xu, Y. T. Zhang, X. G. Xu, D. J. Wang, T. D. Xu, and D. Y. Li, “Role of Toll-like receptor 4/MAPKs pathway on monocyte chemoattractant protein-1 secretion induced by oxidized low density lipoprotein in vascular smooth muscle cells,” Chinese Journal of Pathophysiology, vol. 26, no. 5, pp. 848–852, 2010. View at Google Scholar
  50. J. Tian, Y. Wang, Z. He, Y. Gao, J. E. Rundhaug, and X. Wang, “Hydroxyethyl starch (130 kD) inhibits toll-like receptor 4 signaling pathways in rat lungs challenged with lipopolysaccharide,” Anesthesia and Analgesia, vol. 113, no. 1, pp. 112–119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. M. J. Meng, Q. H. Yang, Q. Wang et al., “Effects of different therapeutic methods and typical recipes on activation of ERK1/2 in Kupffer cells of rats with fatty liver,” Chinese Journal of Pathophysiology, vol. 23, no. 8, pp. 1551–1555, 2007. View at Google Scholar
  52. Q. H. Yang, J. Ou, S. Y. Sun et al., “Effects of soothing liver and invigorating spleen recipes of TCM on expression of PI3K p85α protein in hepatocyte of rats with non-alcoholic fatty liver disease,” Journal of Guangdong College of Pharmacy, vol. 25, no. 1, pp. 62–67, 2009. View at Google Scholar
  53. Y. Q. Li, Q. H. Yang, W. N. Xie, and G. Y. Ji, “Clinical study on soothing liver and invigorating spleen method in treating of non-alcoholic fatty liver disease in 35 cases,” Journal of Traditional Chinese Medicine, vol. 48, no. 9, pp. 824–825, 2007. View at Google Scholar
  54. Q. H. Yang, Y. C. Zhou, T. M. Guo et al., “Effects of different therapeutic methods and typical recipes on blood lipid of rats with fatty liver disease,” Journal of New Chinese Medicine, vol. 36, no. 5, pp. 74–75, 2004. View at Google Scholar